What does an end-stage multiple myeloma diagnosis mean? An “end-stage” multiple myeloma diagnosis generally means that the disease has become advanced, difficult to control, or resistant to available treatments. It does not automatically mean that death is imminent. Prognosis varies considerably according to disease biology, previous treatments, response to therapy, complications, overall health, and available treatment options.
I know this distinction personally. In September 1997, my oncologist told me that my multiple myeloma was end-stage. I am still here. Looking back, I think that Dr. Rassiga intended to tell me that she could not control my myeloma. I took her to mean that there were NO therapies that could control my MM. I think I misunderstood her.
Remember that “end-stage” can be used conversationally to describe advanced/refractory disease and is not necessarily synonymous with a specific formal myeloma stage.
Understanding what your stage is as an MM survivor is important.
Multiple myeloma remains generally incurable, and many patients eventually experience relapse or treatment-resistant disease. However, the course of myeloma varies substantially from person to person, and “end-stage” should not be interpreted as a precise prediction of how long someone has to live.
Similarly, it’s important to stress that a diagnosis of stage 3 myeloma is not a death sentence either. I’ve seen many people diagnosed at stage 3 and live long lives as MM survivors.
End-Stage Multiple Myeloma: 5 Things to Know
- “End-stage” does not necessarily mean death is imminent.
- Relapsed/refractory myeloma can still have treatment options.
- Symptoms and complications often become increasingly important.
- Palliative care can be provided alongside active cancer treatment.
- Hospice is different from palliative care and is generally focused on comfort when life-prolonging treatment is no longer the goal.
That fifth point is particularly important.
The International Myeloma Foundation explicitly distinguishes palliative care from hospice and notes that palliative care can occur alongside myeloma treatment.
End-Stage vs. Relapsed/Refractory Multiple Myeloma
These terms aren’t necessarily interchangeable.
The NCI’s current multiple myeloma treatment guidance specifically discusses relapsed or refractory disease and lists additional therapeutic approaches that may be considered depending upon the patient’s circumstances.
What Happens in End-Stage Multiple Myeloma?
I consider “end-stage myeloma” to be more about symptoms than about dying. Meaning, if controlling your MM is difficult then you may be more prone to serious side effects.
Bone problems
- bone pain
- fractures
- spinal complications
Kidney problems
- declining kidney function
- renal failure
Blood-count problems
- anemia
- thrombocytopenia
- infection risk
Calcium problems
Infection
- immunosuppression
- recurrent infections
Recent end-of-life research in myeloma found renal failure, hypercalcemia, and uncontrolled sepsis among important complications in patients near death.
Palliative Care Is Not the Same as Giving Up
Learn more about early palliative care for multiple myeloma.
Current research supports integrating palliative care into multiple myeloma management rather than waiting until the final days of life. A 2025 review specifically describes palliative care as part of management across the disease continuum.
A retrospective study also found that early palliative care was associated with better quality-of-care indicators and reduced pain intensity without a difference in survival.
Palliative Care vs. Hospice for Multiple Myeloma
| Palliative Care |
Hospice |
| Can begin at any stage |
Generally associated with end-of-life care |
| Can accompany cancer treatment |
Usually when disease-directed treatment is no longer the primary goal |
| Focuses on symptoms and quality of life |
Focuses primarily on comfort and quality of life |
| Does not mean you are dying |
Usually indicates limited life expectancy |
This distinction is extremely important because many patients equate the word palliative with “there is nothing left to do.”
I will say that I understand the articles linked and excerpted below because of living with multiple myeloma since 1994.. In a nutshell, multiple myeloma patients with stronger spiritual grounding do better. For the record, stronger spiritual grounding can be many things.
If your oncologist tells you that you are end-stage, you may freak out (I did…). Try to think through your situation.
Looking back at my “end-stage” experiences, I now think differently about a diagnosis of end-stage MM.
Questions to Ask After an End-Stage Myeloma Diagnosis
- What does “end-stage” mean in my particular case?
- Is my myeloma relapsed, refractory, or both?
- What treatments remain?
- What is the expected benefit of another treatment?
- What are the likely side effects?
- What symptoms should cause me to call immediately?
- Should I meet with palliative care now?
- Should we discuss hospice?
- What should my family expect?
- Should I get a second opinion from a myeloma specialist?
- Are clinical trials appropriate?
Is your MM advanced? To learn more about evidence-based mind-body therapies, scroll down the page, ask me a question, and I will reply to you ASAP.
Thank you,
David Emerson
- MM Survivor
- MM Coach
- Director PeopleBeatingCancer
“Individual meaning-centered psychotherapy (IMCP) significantly improves psychological outcomes and spiritual well-being among patients with advanced cancer (multiple myeloma) compared with enhanced usual care (EUC) or supportive psychotherapy (SP), according to a study published in Cancer.
Many patients with advanced cancer experience spiritual and existential distress, and the number of psychotherapeutic interventions with an emphasis on spirituality is growing. Previous studies evaluating these interventions, however, have led to mixed results and were never completed in large, systematic clinical trials…
Patients in the IMCP arm had small-to-moderate but significant treatment effects for 5 of the 7 outcome variables assessed compared to patients receiving EUC (no-treatment comparison): quality of life, spiritual well-being, sense of meaning, desire for hastened death, and anxiety…
“For cancer patients, religion and spirituality (R/S) measures are associated with measures of physical, mental, and social health outcomes, according to three reviews published online Aug. 10 in Cancer…
“When we took a closer look, we found that patients with stronger spiritual well-being, more benign images of God (such as perceptions of a benevolent rather than an angry or distant God), or stronger beliefs (such as convictions that a personal God can be called upon for assistance) reported better social health,” Sherman said in a statement.”
“Many researchers have conducted literature reviews on the impact of religion and spirituality on cancer patients’ (MM) health, but none have taken such thorough and painstaking efforts to analyze the data in such detail.
“To date, this series of meta-analyses represents the most comprehensive summary and synthesis of a rapidly growing area of psychosocial oncology: the role of religion and spirituality for patients and survivors managing the experience of cancer,” said Salsman…”
“Patients with advanced myeloma experience a high symptom burden particularly near the end of life, making timely hospice use crucial. Little is known about the quality and determinants of end-of-life care for this population, including whether potential increases in hospice use are also accompanied by “late” enrollment (≤ 3 days before death).
Using the Surveillance, Epidemiology, and End-Results-Medicare database, we identified patients ≥ 65 years diagnosed with myeloma between 2000 and 2013 who died by December 31, 2013. We assessed prevalence and trends in hospice use, including late enrollment. We also examined six established measures of potentially aggressive medical care at the end of life. Independent predictors of late hospice enrollment and aggressive end-of-life care were assessed using multivariable logistic regression analyses…
Research
1. End-of-life management of multiple myeloma
A particularly valuable recent paper:
Sesques et al., 2024 — End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy
It examined 100 deceased myeloma patients and reported disease progression and complications including sepsis, renal failure and hypercalcemia.
PubMed — End-of-life management of multiple myeloma patients
2. Early palliative care
PubMed — Early palliative care versus usual haematological care in multiple myeloma
This is particularly useful for supporting your argument that palliative care shouldn’t automatically be interpreted as “the end.”
3. Palliative care in multiple myeloma
PubMed — Palliative Care in Patients With Multiple Myeloma
Useful for your symptom-management and advance-care-planning discussion.
4. Quality of end-of-life care
PubMed — Quality of end-of-life care in multiple myeloma
This provides useful evidence regarding hospitalization, chemotherapy and aggressive end-of-life care.
5. Symptom burden and quality of life
PubMed — Disease-related symptoms, palliative care concerns and quality of life in multiple myeloma
This is particularly useful for your sections on fatigue, pain, breathlessness and advanced-disease symptom burden.
6. Current treatment guidance
NCI — Multiple Myeloma Treatment (PDQ)
Use this to keep the treatment-options discussion current, particularly around relapsed/refractory disease.
